MUPIROCIN

Search structure


Trade Names:	BACTROBAN CENTANY MUPIROCIN
Synonyms:	Bactoderm Bactroban BRL 4910A BRL-4910A Centany Mupirocin NSC-759182 Pseudomonic acid Trans-pseudomonic acid Turixin
Status:	Approved (1987)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	D06AX09
UNII:	D0GX863OA5

Structure


InChI Key	MINDHVHHQZYEEK-HBBNESRFSA-N
Smile	C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O
InChI	InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C26H44O9
Molecular Weight	500.63
AlogP	2.59
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	16.0
Polar Surface Area	146.05
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	35.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Isoleucyl-tRNA synthetase inhibitor	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Ligase	-	1	-	60-15000	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Infections	4	D007239	ClinicalTrials
Telangiectasia, Hereditary Hemorrhagic	3	D013683	ClinicalTrials
Staphylococcal Infections	3	D013203	ClinicalTrials
Epistaxis	3	D004844	ClinicalTrials
Cystic Fibrosis	2	D003550	ClinicalTrials
Hemangioma	2	D006391	ClinicalTrials
Radiodermatitis	2	D011855	ClinicalTrials
Osteomyelitis	0	D010019	ClinicalTrials

Related Entries

Salt

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Nervous system disorders Headache	9.0
Infections and infestations Rhinitis	6.0
Respiratory, thoracic and mediastinal disorders Upper respiratory tract congestion	5.0
Gastrointestinal disorders Nausea	4.9
Gastrointestinal disorders Pharyngitis	4.0
Gastrointestinal disorders Dysgeusia	3.0
Skin and subcutaneous tissue disorders Pruritus	2.4
Respiratory, thoracic and mediastinal disorders Cough	2.0
General disorders and administration site conditions Pain	2.0
Nervous system disorders Headache	1.7
Skin and subcutaneous tissue disorders Pruritus	1.0
Infections and infestations Rhinitis	1.0
Gastrointestinal disorders Dysgeusia	0.8
Gastrointestinal disorders Pharyngitis	0.5

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Injury, poisoning and procedural complications	29.8
General disorders and administration site conditions	20.3
Skin and subcutaneous tissue disorders	12.06
Respiratory, thoracic and mediastinal disorders	5.7
Gastrointestinal disorders	5.64
Nervous system disorders	5.24
Immune system disorders	3.59
Vascular disorders	3.0
Eye disorders	2.87
Infections and infestations	2.44
Product issues	2.14

Cross References

Resources	Reference
CAS NUMBER	12650-69-0
ChEBI	7025
ChEMBL	CHEMBL719
DrugBank	DB00410
DrugCentral	1857
EPA CompTox	DTXSID0046438
FDA SRS	D0GX863OA5
Human Metabolome Database	HMDB0014554
Guide to Pharmacology	10916
KEGG	C11758
PDB	MRC
PharmGKB	PA164764568
PubChem	446596
SureChEMBL	SCHEMBL3291
ZINC	ZINC000004102194

CONTENTS